CONSOLIDATED STATEMENTS OF EQUITY - USD ($)	Total	Series A Preferred	Series B1 Preferred Stock	Series B Preferred Stock	Common Stock	Common Stock Series A Preferred	Common Stock Series B1 Preferred Stock	Common Stock Series B Preferred Stock	Preferred stock	Preferred stock Series A Preferred	Additional Paid-In Capital	Additional Paid-In Capital Series B1 Preferred Stock	Additional Paid-In Capital Series B Preferred Stock	Retained Earnings	Retained Earnings Series B Preferred Stock	Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2020					45,555,000					420,000
Beginning balance at Dec. 31, 2020	$ 5,925,000				$ 46,000					$ 0	$ 94,570,000			$ (90,009,000)		$ 1,318,000
Increase (Decrease) in Stockholders' Equity
Exercise of options/B1 warrants (in shares)					23,000		1,080,000
Exercise of options/ B1 warrants	0		$ 2,758,000		$ 0		$ 1,000				0	$ 2,757,000
Share based compensation expense	150,000										150,000
Exchanges of Series B Preferred stock to common (in shares)								2,359,000
Exchanges of Series B Preferred stock to common				$ 4,746,000				$ 2,000					$ 4,114,000		$ 630,000
Conversion of Series B Preferred stock to common (in shares)								638,000
Conversion of Series B Preferred stock to common				1,979,000				$ 1,000					1,978,000
Conversion of Series B1 Preferred stock to common (in shares)							2,087,000
Conversion of Series B1 Preferred stock to common			3,256,000				$ 2,000					3,254,000
Dividends on Series B and B1	(372,000)													(372,000)
Accretion of discount on Series B and B1	(224,000)													(224,000)
Accretion of redeemable non-controlling interest to redemption value	(373,000)													(373,000)
Net income (loss)	2,965,000													974,000		1,991,000
Less: amount attributable to redeemable non-controlling interest	(1,542,000)															(1,542,000)
Ending balance (in shares) at Mar. 31, 2021					51,742,000					420,000
Ending balance at Mar. 31, 2021	19,268,000				$ 52,000					$ 0	106,823,000			(89,374,000)		1,767,000
Beginning balance (in shares) at Dec. 31, 2020					45,555,000					420,000
Beginning balance at Dec. 31, 2020	5,925,000				$ 46,000					$ 0	94,570,000			(90,009,000)		1,318,000
Increase (Decrease) in Stockholders' Equity
Exercise of options/B1 warrants (in shares)					528,368
Net income (loss)	(2,347,000)
Ending balance (in shares) at Sep. 30, 2021					63,003,000				386,000
Ending balance at Sep. 30, 2021	37,342,000				$ 63,000				$ 0		136,906,000			(101,475,000)		1,848,000
Beginning balance (in shares) at Mar. 31, 2021					51,742,000					420,000
Beginning balance at Mar. 31, 2021	19,268,000				$ 52,000					$ 0	106,823,000			(89,374,000)		1,767,000
Increase (Decrease) in Stockholders' Equity
Exercise of options/B1 warrants (in shares)					505,000		157,000
Exercise of options/ B1 warrants	229,000		1,634,000		$ 0						229,000	1,634,000
Exercise of options to common- unissued	475,000										475,000
Leverage Lubricants contribution	(13,000)															(13,000)
Exercise of B1 warrants-unissued	1,186,000										1,186,000
Share based compensation expense	205,000										205,000
Conversion of Series A Preferred stock to common (in shares)						28,000				(28,000)
Conversion of Series A Preferred stock to common		$ 0
Conversion of Series B Preferred stock to common (in shares)								1,842,000
Conversion of Series B Preferred stock to common				5,709,000				$ 2,000					5,707,000
Conversion of Series B Preferred stock to common-unissued				760,000									$ 760,000
Conversion of Series B1 Preferred stock to common (in shares)							5,635,000
Conversion of Series B1 Preferred stock to common			8,791,000				$ 6,000					8,785,000
Accretion of discount on Series B and B1	(284,000)													(284,000)
Accretion of redeemable non-controlling interest to redemption value	(387,000)													(387,000)
Net income (loss)	(15,957,000)													(19,375,000)		3,418,000
Less: amount attributable to redeemable non-controlling interest	(3,113,000)															(3,113,000)
Ending balance (in shares) at Jun. 30, 2021					59,909,000					392,000
Ending balance at Jun. 30, 2021	18,503,000				$ 60,000					$ 0	125,804,000			(109,420,000)		2,059,000
Increase (Decrease) in Stockholders' Equity
Exercise of options/B1 warrants (in shares)					1,267,000		1,576,000
Exercise of options/ B1 warrants	1,482,000		9,363,000		$ 1,000		$ 2,000				1,481,000	9,361,000
Exercise of options to common- unissued	3,000										3,000
Distribution to noncontrolling shareholder	(169,000)															(169,000)
Leverage Lubricants contribution	2,000															2,000
Share based compensation expense	257,000										257,000
Conversion of Series A Preferred stock to common (in shares)						6,000		245,000		(6,000)
Conversion of Series A Preferred stock to common		0		$ 0
Accretion of redeemable non-controlling interest to redemption value	(415,000)													(415,000)
Net income (loss)	10,645,000													8,360,000		2,285,000
Less: amount attributable to redeemable non-controlling interest	(2,329,000)															(2,329,000)
Ending balance (in shares) at Sep. 30, 2021					63,003,000				386,000
Ending balance at Sep. 30, 2021	37,342,000				$ 63,000				$ 0		136,906,000			(101,475,000)		1,848,000
Beginning balance (in shares) at Dec. 31, 2021					63,288,000					386,000
Beginning balance at Dec. 31, 2021	30,066,000				$ 63,000					$ 0	138,620,000			(110,614,000)		1,997,000
Increase (Decrease) in Stockholders' Equity
Exercise of options/B1 warrants (in shares)					60,000		1,113,000
Exercise of options/ B1 warrants	76,000		0				$ 1,000				76,000	(1,000)
Share based compensation expense	250,000										250,000
Conversion of Series A Preferred stock to common (in shares)						5,000				(5,000)
Conversion of Series A Preferred stock to common		0
Reclassification of derivative liabilities	78,789,000										78,789,000
Accretion of redeemable non-controlling interest to redemption value	(422,000)													(422,000)
Net income (loss)	(808,000)													(4,547,000)		3,739,000
Less: amount attributable to redeemable non-controlling interest	(3,769,000)															(3,769,000)
Ending balance (in shares) at Mar. 31, 2022					64,466,000					381,000
Ending balance at Mar. 31, 2022	104,182,000				$ 64,000					$ 0	217,734,000			(115,583,000)		1,967,000
Beginning balance (in shares) at Dec. 31, 2021					63,288,000					386,000
Beginning balance at Dec. 31, 2021	30,066,000				$ 63,000					$ 0	138,620,000			(110,614,000)		1,997,000
Increase (Decrease) in Stockholders' Equity
Exercise of options/B1 warrants (in shares)					561,317
Conversion of Series A Preferred stock to common (in shares)					10,165,149
Conversion of Series A Preferred stock to common					$ 59,822,000
Net income (loss)	(42,421,000)
Ending balance (in shares) at Sep. 30, 2022					75,610,000					0
Ending balance at Sep. 30, 2022	120,340,000				$ 76,000					$ 0	278,930,000			(160,354,000)		1,688,000
Beginning balance (in shares) at Mar. 31, 2022					64,466,000					381,000
Beginning balance at Mar. 31, 2022	104,182,000				$ 64,000					$ 0	217,734,000			(115,583,000)		1,967,000
Increase (Decrease) in Stockholders' Equity
Exercise of options/B1 warrants (in shares)					498,000
Exercise of options/ B1 warrants	554,000				$ 1,000						553,000
Exercise of options to common- unissued	3,000										3,000
Distribution to noncontrolling shareholder	(380,000)															(380,000)
Adjustment of redeemable non controlling interest	0										29,000			(29,000)
Share based compensation expense	324,000										324,000
Conversion of Series A Preferred stock to common (in shares)					10,165,000	381,000				(381,000)
Conversion of Series A Preferred stock to common	59,822,000	$ 1,000			$ 10,000	$ 1,000					59,812,000
Accretion of redeemable non-controlling interest to redemption value	(6,000)													(6,000)
Net income (loss)	(63,782,000)													(66,970,000)		3,188,000
Less: amount attributable to redeemable non-controlling interest	(3,023,000)															(3,023,000)
Ending balance (in shares) at Jun. 30, 2022					75,510,000					0
Ending balance at Jun. 30, 2022	97,695,000				$ 76,000					$ 0	278,455,000			(182,588,000)		1,752,000
Increase (Decrease) in Stockholders' Equity
Exercise of options/B1 warrants (in shares)					4,000		96,000
Exercise of options/ B1 warrants	0		$ 0		$ 0		$ 0				0	$ 0
Exercise of options to common- unissued	97,000										97,000
Share based compensation expense	378,000										378,000
Net income (loss)	22,170,000													22,234,000		(64,000)
Ending balance (in shares) at Sep. 30, 2022					75,610,000					0
Ending balance at Sep. 30, 2022	$ 120,340,000				$ 76,000					$ 0	$ 278,930,000			$ (160,354,000)		$ 1,688,000